ArticleBMC cancer2026

EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.

Fei Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.